Physician

Abbas Y. Rampurwala, M.D.

According to 2025 Medicare claims, Abbas Rampurwala, M.D. (NPI: 1043364938) practices interventional cardiology in the Elgin, IL market, with the plurality of this provider's patient population coming from Kane, IL. This provider's primary affiliated billing organization is METRO HEART & VASCULAR INSTITUTE LTD (NPI: 1811327844; TIN: 463590084) and primary practice location at 60102-5916. Rampurwala is affiliated with the Advocate Physician Partners Accountable Care, Inc. (ACO ID: A1033), participating under the MSSP model.

Rampurwala's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 845 traditional Medicare patients, billed 3,746 HCPCS/CPT codes, and received $239,369 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,224 prescription claims across 588 beneficiaries totaling $858,043 in drug costs, led by Eliquis (Apixaban). Open Payments data shows 4 records totaling $73. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $120,302 to $239,369. Similarly, Part D prescription costs have moved sharply higher in recent years, from $42,745 to $858,043. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	787	2,398	$120,302
2016	719	2,722	$168,542
2017	823	3,006	$196,658
2018	869	3,756	$237,082
2019	962	3,792	$245,599
2020	857	3,764	$235,366
2021	904	3,854	$258,644
2022	845	3,206	$217,513
2023	930	3,892	$241,285
2024	845	3,746	$239,369

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	148	1,024	$42,745
2016	210	1,263	$70,397
2017	269	2,041	$113,939
2018	339	2,710	$231,508
2019	351	2,776	$298,358
2020	361	2,852	$336,524
2021	406	3,165	$451,770
2022	450	3,363	$653,672
2023	541	3,811	$740,980
2024	588	4,224	$858,043

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	327	571	$92
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	289	301	$76
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	247	409	$12
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	243	253	$10
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	291	548	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	300	19,574	$376,014
Jardiance	Empagliflozin	90	7,357	$143,583
Entresto	Sacubitril/Valsartan	90	6,030	$130,616
Xarelto	Rivaroxaban	48	3,587	$65,288
Repatha Sureclick	Evolocumab	26	1,008	$19,283

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$73	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Abbas Y. Rampurwala, M.D.?

Tedicare shows public-source Medicare data for Abbas Y. Rampurwala, M.D. (NPI 1043364938), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Abbas Y. Rampurwala, M.D. have ACO affiliation data?

Abbas Y. Rampurwala, M.D. is shown with ACO affiliation data for Advocate Physician Partners Accountable Care, Inc. (MSSP, ACO ID A1033).

What billing organization is linked to Abbas Y. Rampurwala, M.D.?

Abbas Y. Rampurwala, M.D. is linked to METRO HEART & VASCULAR INSTITUTE LTD (billing NPI 1811327844) in the available physician profile data.

Does Abbas Y. Rampurwala, M.D. have Open Payments data?

Abbas Y. Rampurwala, M.D. has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.